ANI Pharmaceuticals (ANIP)
Develops rare-disease therapies, niche generics, and established prescription brands.
Something off on this page? Send us feedback.
Develops, manufactures, and markets rare-disease therapies, generic drugs, and established prescription brands. Purified Cortrophin Gel anchors Rare Disease and Brands, while a broad generics portfolio and U.S. manufacturing base support launches and cash generation; key products rely on FDA approvals and, in several cases, third-party supply.
Develops, manufactures, and markets prescription medicines through Rare Disease and Brands and Generics and Other. Purified Cortrophin Gel anchors the rare-disease portfolio across certain autoimmune disorders and nephrotic syndrome, while ILUVIEN serves retinal disease and acquired brands cover established therapies. The commercial footprint is centered in the United States, with direct retina operations in selected European markets and partnerships elsewhere.
Builds the generics portfolio through internal R&D, acquired drug applications and product rights, partnerships, and recurring launches. Three U.S. plants support oral solids, liquids, topicals, controlled substances, and other specialized formulations. The model depends on FDA approvals and inspections, competitive generic pricing, reliable launches, and third-party manufacturing; several key products, including Cortrophin Gel and ILUVIEN, use external suppliers, sometimes from a single source.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $104 |
| Aug 10, 2026 | Guggenheim | Reiterate | Rating: —Target: $124 | Target: $119 |
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $91 | Target: $90 |
| Jul 16, 2026 | Canaccord Genuity | Target | Target: — | Target: $91 |
| Jan 16, 2026 | Guggenheim | Reiterate | Rating: —Target: $114 | Target: $124 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $375.9M · Total debt $330.3M · Total assets $1.49B · Shareholders' equity $597.2M
- Revenue
- $266.0M
- Operating income
- $40.5M
- Net income
- $24.7M
No dividends on record.
| Institutions | ≈ 198.67% | 45.64M shares | |
|---|---|---|---|
| 315 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 7.78% | 1.79M shares | |
| 16 holders · as of Sep 16, 2026 | |||
| Adds to | 206.45% | ||
22.97M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 206.45%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 25.76% | 2.96M · 2.96M | as of Jun 30, 2026 |
Soleus Capital Management, L.P.Institution | 7.56% | 867,760 · 867,760 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 7.30% | 838,224 · 838,224 | as of Jun 30, 2026 |
State Street CorpInstitution | 7.24% | 831,647 · 831,647 | as of Jun 30, 2026 |
Tang Capital Management LLCInstitution | 6.16% | 707,500 · 707,500 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Nikhil Lalwani | director, officer: PRESIDENT & CEO | −5,400 | $71.00 |
| Sep 14, 2026 | Meredith Cook | officer: SR. VP, GENERAL COUNSEL & SEC. | −500 | $70.79 |
| Sep 11, 2026 | Jeanne Thoma | director | −1,000 | $71.53 |
| Aug 31, 2026 | Stephen P. Carey | officer: SVP & CFO | −2,850 | $72.80 |
| Aug 25, 2026 | Nikhil Lalwani | director, officer: PRESIDENT & CEO | −5,400 | $74.30 |
- Teva (ADR)
Large U.S. generic-drug rival named in filings.
- Viatris
Scale competitor across generics and established brands.
- AbbVie
Ozurdex and Humira overlap the retina franchise.
- Amneal Pharmaceuticals
Mid-cap U.S. generics and specialty Rx overlap.
- Regeneron
EYLEA franchise pressures ILUVIEN in DME.
- Bausch + Lomb
XIPERE and Retisert overlap NIU-PS steroid care.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals | $77.91 | 0.00% | $1.79B | 17.0 | 8.3 | 1.8 | +25.9% |
| Teva (ADR) | $39.60 | +0.28% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Viatris | $17.01 | −0.99% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| AbbVie | $265.32 | +0.02% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Amneal Pharmaceuticals | $19.79 | +1.46% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Regeneron | $803.92 | −0.02% | $82.23B | 19.7 | 13.3 | 5.3 | +16.7% |
| Bausch + Lomb | $17.32 | −0.06% | $6.00B | — | 17.4 | 1.1 | +9.1% |
| Median | 54.1 | 15.7 | 2.4 | +9.5% |